This invention establishes a novel method of therapeutic delivery to target tumor cells by macropinocytosis.
Selective and efficient delivery of therapeutic agents to tumor cells is often challenging. To improve drug efficacy, a method to deliver an effective dose of therapeutic agents to tumor cells with high specificity is needed. Tumor cells have been shown to preferentially engage a process known as macropinocytosis to internalize nutrients from the environment. Therefore, UCSF inventors sought to exploit this pathway by 1) identifying antibodies that are efficiently internalized by macropinocytosis in tumor cells, and 2) developing antibody-toxin conjugates capable of killing these tumor cells.
This novel invention provides the following advantages:
Scientists at the University of California, San Francisco have developed a high-throughput method that leverages both phage antibody display libraries and high-content analysis (HCA) screening to identify antibodies that are rapidly and efficiently internalized by cells through the macropinocytosis pathway. These antibodies can then be conjugated to a variety of molecules including cytotoxins, nanoparticles, radionuclides, and siRNAs/miRNAs to create a novel class of potent targeted therapeutics.
Targeted cancer therapy development
To develop and commercialize this technology as a novel method of therapeutic delivery to target tumor cells
Preclinical
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 11,447,563 | 09/20/2022 | 2014-200 |
Australia | Issued Patent | 2015287749 | 06/24/2021 | 2014-200 |
Switzerland | Issued Patent | 3169707 | 12/02/2020 | 2014-200 |
Germany | Issued Patent | 602015062995.1 | 12/02/2020 | 2014-200 |
France | Issued Patent | 3169707 | 12/02/2020 | 2014-200 |
United Kingdom | Issued Patent | 3169707 | 12/02/2020 | 2014-200 |
Ireland | Issued Patent | 3169707 | 12/02/2020 | 2014-200 |
United States Of America | Issued Patent | 10,550,195 | 02/04/2020 | 2014-200 |
Canada | Published Application | 2014-200 | ||
Additional Patents Pending
Cancer, Tumor Targeting, Macropinocytosis, Internalizing Antibody